Solventum (SOLV) has quietly outperformed the broader market this year, with the stock up about 22% year to date, even after a recent pullback over the past week. See our latest analysis for Solventum ...

Solventum (SOLV) has just unveiled a substantial share buyback initiative, with the board authorizing the repurchase of up to $1 billion in common stock. The program, which carries no time limit, ...

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million ...

On Thursday, Solventum (NYSE:SOLV) hosted its 2025 Investor Day, during which it outlined its strategic priorities, its business segments, and its long-range plan (LRP) to drive growth and value ...

Solventum, Minnesota’s newest Fortune 500 company, is finding its footing after starting its first full year of operations on shakier ground. The 3M spinoff commenced 2025 with a deflated stock, which ...